整理 | GLP1减重宝典内容团队 5月16日，诺和诺德公司宣布将更换首席执行官 Lars Fruergaard Jorgensen，原因是该公司正应对减肥药物市场日益激烈的竞争——尤其是来自 礼来公司的竞争——以及其旗舰产品 Wegovy 注射剂的一系列挫折。Wegovy 注射剂曾彻底改变了减肥疗法，并使这家丹麦公司跻身欧洲企业 巨头之列。 这一意外决定标志着诺和诺德公司领导层的罕见变动，诺和诺德公司以稳定和共识驱动的文化而闻名。 此前一年，诺和诺德股价暴跌 53%，市 值蒸发超过 3000 亿美元。这家制药商面临着新减肥疗法临床试验结果令人失望，以及礼来公司竞争药物的快速推进。 该公司在周五的一份声明中表示："鉴于近期市场动态、股价下跌以及诺和诺德基金会的指导，董事会和Lars Fruergaard Jorgensen一致认为， 启动首席执行官过渡符合公司及其股东的最佳利益。" 公告发布后，诺和诺德股价下跌约4%，而礼来股价在美股早盘交易中上涨1.4%。 Jorgensen将暂时留任，以确保领导层的平稳过渡，诺和诺德也确认，其继任者选拔工作已在启动。 诺和诺德很少更换首席执行官。包括Jorgensen本人 ...

Core Viewpoint - GLP-1 receptor agonists (GLP-1RAs) have shown potential not only in controlling blood sugar and promoting weight loss but also in reducing the risk of obesity-associated cancers (OACs) in type 2 diabetes patients [2][3]. Research Background and Methodology - The study was motivated by the relationship between obesity and cancer, focusing on the potential of GLP-1RAs to lower the risk of OACs due to their effectiveness in weight reduction [4]. - Data from 1.65 million type 2 diabetes patients, who had not been diagnosed with 13 types of OACs, were analyzed using the TriNetX platform, which includes electronic health records from 64 healthcare institutions in the U.S. [4][5]. Comparison with Insulin - The analysis included 1.09 million patients using either GLP-1RAs or insulin, revealing that GLP-1RAs significantly reduced the risk of 10 types of OACs compared to insulin [6]. - Specific reductions in cancer risk associated with GLP-1RAs include: - Gallbladder cancer risk reduced by 65% - Meningioma risk reduced by 63% - Pancreatic cancer risk reduced by 59% - Hepatocellular carcinoma risk reduced by 53% - Ovarian cancer risk reduced by 48% - Colorectal cancer risk reduced by 46% - Multiple myeloma risk reduced by 41% - Esophageal cancer risk reduced by 40% - Endometrial cancer risk reduced by 26% - Kidney cancer risk reduced by 24% [6][7]. Comparison with Metformin - When comparing GLP-1RAs with metformin, no significant reduction in cancer risk was observed for 12 types of cancers, but there was a noted 54% increase in kidney cancer risk among GLP-1RA users [8]. Research Limitations - The study's retrospective nature and reliance on electronic health records introduce inherent limitations, such as biases and uncontrolled confounding factors [9][10]. Research Applications - Despite limitations, findings suggest that GLP-1RAs may address a broader range of health issues, with recent FDA approvals for drugs like Wegovy to reduce cardiovascular risks in overweight or obese patients [11]. - Companies like Eli Lilly are expanding their GLP-1 therapies to treat conditions such as obstructive sleep apnea, indicating ongoing innovation in this therapeutic area [13].

腰围超标、体重增加，甚至部分人已被慢性疾病困扰……3月9日，国家卫生健康委员会主任雷海潮在民生主题记者会上提出，将持续推进"体 重管理年"专项行动，并鼓励各级医疗机构开设体重管理门诊。消息一出，体重门诊迅速成为网络和现实中的热门话题。 当前，许多地区的医院已纷纷设立体重管理门诊或多学科减重联合门诊。那么，体重门诊到底能帮助大家解决哪些健康难题？会涉及哪些专业 领域？又有哪些人群适合前来咨询？带着这些问题，记者在多地进行了深入走访。 ▍减肥门诊能够帮你解决哪些问题？ 家住北京海淀区的王女士，最近带着16岁的儿子乐乐来到北京大学人民医院医学营养减重门诊。乐乐的BMI（体重指数）高达40.3，属于重度 肥胖。 "孩子平时喜欢吃炸鸡腿等油腻食物，蔬菜和水果吃得很少。"该院临床营养科主任柳鹏在详细了解后发现，乐乐的饮食结构存在明显问题。经 过检查，乐乐的内脏脂肪超标，血尿酸水平也偏高。如果不及时调整，很容易诱发脂肪肝、转氨酶升高、痛风以及其他代谢疾病。 厦门大学附属第一医院内分泌糖尿病科主任医师刘长勤也表示，减重过程中体重容易反弹，因此需要定期随访，由多学科医生与患者共同讨论并动态调 整减重方案。 早在2019年，厦门 ...

Core Insights - Andrew Dudum, co-founder of Hims & Hers, transitioned from a background in music to entrepreneurship, driven by a passion for business and innovation [1][3] - Hims & Hers has emerged as a leading telehealth provider, focusing on destigmatizing healthcare and providing convenient access to medical services [5][6] Group 1: Early Life and Education - Andrew Dudum was born in 1988 in San Francisco and was influenced by a family environment rich in entrepreneurial spirit [1] - He attended the Wharton School of the University of Pennsylvania, where he co-founded his first business, LendforPeace, aimed at supporting small businesses in the Middle East [1][3] Group 2: Founding Atomic Labs - In 2013, Dudum co-founded Atomic Labs, a unique company that combines startup incubation and venture capital, focusing on creating companies from internal concepts [4] - Atomic Labs has successfully launched over ten startups, with Hims being one of the most notable successes [4] Group 3: Development of Hims & Hers - Hims was founded in 2016 to address gaps in the healthcare market, particularly in the areas of hair loss and sexual health, initially targeting male consumers [5] - The brand has since expanded to include female healthcare services and aims to provide a broad range of telehealth solutions [5] Group 4: Financial Growth and Market Position - Hims & Hers went public in 2021 through a merger with a SPAC, achieving a valuation of $1.6 billion at the time of listing [5] - As of May 2023, Hims & Hers reported a revenue increase of 111%, reaching $586 million, with net income rising from $11.1 million to $49.5 million [7]

"体重异常很容易引发高血压、糖尿病、心脑血管疾病、脂肪肝，甚至部分癌症也与体重异常密切相关。" "有些人腰围明显超标、体重超重，甚至已经出现慢性疾病……这种情况下，建议寻求专业医生和正规医疗机构的帮助。" ▍怎么判断自己是否超重肥胖？ 超重和肥胖的形成受到多种因素的共同影响，包括遗传基因、饮食结构、运动量、生活方式以及社会环境的变化等。 体质指数（BMI）是衡量人体胖瘦程度的重要指标，其计算公式为：BMI=体重（kg）/身高（m）²。 我国健康成年人的BMI正常范围为18.5至24。当BMI在24到28之间时，被判定为超重；若BMI达到或超过28，则属于肥胖。 在肥胖中，又可根据BMI数值划分为轻度肥胖、中度肥胖、重度肥胖和极重度肥胖。 ▍如何吃才能健康减肥？ 此前，国家卫健委发布了《成人肥胖食养指南（2024年版）》，为科学减肥提供了详细指导。这份指南不仅手把手教你如何健康减重，还针对 全国不同地区，列举了具有地域特色的食谱示例，并标注了每份食谱的"总能量"。比如，东北地区春季推荐"铁锅炖鱼""菜包饭"，西北地区则 有"臊子面""油泼面"等地方美食。 优先推荐这些食物 3月9日，在十四届全国人大三次会议新闻 ...

整理 | GLP1减重宝典内容团队 一项新的荟萃分析显示，用于治疗 2 型糖尿病并帮助减重的药物（如 Ozempic 和 Wegovy）可能显著降低患上任何形式痴呆症的风险。 该研究回顾了 26 项随机临床试验，涵盖超过 16 万名参与者，为 GLP-1 受体激动剂在改善认知方面的潜力提供了进一步证据。 这类药物（包括司美格鲁肽、利拉鲁肽和艾塞那肽）此前已经被发现与轻微降低痴呆风险相关，不过这些发现大多来自观察性研究，而 非临床对照实验。 点击关注，追踪最新GLP-1资讯 此次研究由爱尔兰戈尔韦大学的 Catriona Reddin 领导，团队分析了多项安慰剂对照试验的数据，对象为尚未被诊断患有痴呆或认知障 碍的 2 型糖尿病患者。参与者在试验中使用 GLP-1 药物，并进行了至少六个月的随访。结果显示，与接受安慰剂的组相比，使用这些药 物的群体在痴呆或认知能力下降方面的发病率明显较低。 "虽然这不能替代一项专门针对痴呆的大型随机试验，但确实提供了额外的证据支持这一关联，"未参与该研究的圣路易斯华盛顿大学医 学院的 Ziyad Al-Aly 表示。 由于 2 型糖尿病本身就是痴呆的已知风险因素，有观点认为仅靠 ...

整理 | GLP1减重宝典内容团队 胰高血糖素样肽-1 受体激动剂(GLP-1 RA) 药物的兴起改变了医疗保健格局，引起了广泛关注和采用。根据最近的 KFF 健康追踪调查， 美国八分之一的成年人服用过 GLP-1 RA 药物，突显了其惊人的受欢迎程度。 此外，Truveta的团队还显示GLP-1RA 处方量增加。 这 些药物最初是为治疗 2 型糖尿病而开发的，其适应症已扩大到肥胖症和心血管疾病，从而扩大了其吸引力和实用性。 Truveta想知道这些药物如何在治疗模式中发挥作用，特别是在超重或肥胖人群中。变化的求医行为是否会促使首次诊断的增加或改变患 者与医疗保健系统的互动方式？Truveta与路透社独家合作， 以更好地了解首次 GLP-1 RA 处方后 15 天内患者的首次诊断模 式，并了 解这种情况可能如何随时间发生变化 。 点击关注，追踪最新GLP-1资讯 ▍研究方法 Truveta纳入了 2018 年 1 月至 2024 年 10 月期间首次开具 GLP-1 RA 处方的人群。要求患者最近的 BMI 超过 27（表明超重或肥胖，并 且 BMI 达到适合用 GLP-1 RA 治疗的最低水平）。患者还必须 ...

自国家卫健委在两会记者会上宣布将持续推进"体重管理年"三年行动计划后，浙江省中医院针灸科夜间门诊迎来爆满，甚至连埋线工具都一度告罄。这 一现象，正是中国减重市场在"政策推动+需求激增"双重作用下的真实写照。一场关于全民健康和行业革新的新浪潮正在酝酿，减重机构又该如何抓住这 波机遇，实现自身的跨越与突破？ ▍身材管理不再是个人自律，而是国家行动！ 在当今社会，体重管理的重要性正以前所未有的速度被广泛关注。权威统计显示，我国有超过一半的成年人属于超重人群，这直接导致高血 压、糖尿病以及心血管疾病等慢性病的发病风险大幅上升。 在这样的时代背景下，体重管理已不再只是个人健康选择，而是被提升为国家公共卫生战略的重要一环。 2025年两会期间，体重管理议题成为社会各界关注的焦点。国家卫生健康委主任雷海潮明确表示，将"体重管理年"行动纳入未来三年慢性病防控的核心 举措。由国家卫生健康委牵头，教育部、体育总局等16个部门协同推进：教育部负责在学校普及体重管理知识，体育总局则致力于完善公共体育设施、 推动全民健身活动，共同助力这一全民健康计划的实施。 在这一行动中，多项举措协同展开。单位食堂率先优化饮食结构，积极推广低盐、低脂 ...

Core Viewpoint - Septerna (SEPN.US) experienced a significant pre-market surge of 63%, reaching $10.97 with a trading volume of $65.44 million, indicating strong investor interest in the company's developments in GPCR-targeted therapies [2]. Group 1: Company Developments - Septerna is focused on developing therapies targeting G protein-coupled receptors (GPCRs), which are crucial for the absorption of chemical substances through cell membranes [2]. - Two companies are planning to initiate four potential small molecule therapy development projects targeting specific GPCRs, marking a notable collaboration in the pharmaceutical industry [4]. - Novo Nordisk is known for its weight loss drug Wegovy and is working to solidify its position in the rapidly growing obesity treatment market, projected to reach $150 billion [6]. Group 2: Market Context - GPCRs influence a wide range of physiological processes, including metabolism, secretion, cell growth, and immune responses, highlighting their importance in therapeutic development [3]. - The recent collaboration in the obesity sector follows a significant deal in March, where Roche announced plans to invest up to $5.3 billion with Zealand Pharma to develop and commercialize its obesity candidate drug [4].

Core Viewpoint - The collaboration between Hanyu Pharmaceutical and Shenzhen Carbon Cloud Smart Peptide Technology Co., Ltd. aims to develop a novel peptide drug targeting GLP-1R/GIPR/GCGR for metabolic disease treatment, particularly for weight control [2][3]. Group 1: Collaboration Details - Hanyu Pharmaceutical will handle preclinical research, IND application, clinical trials, and product registration, covering associated costs [3]. - Carbon Cloud Smart Peptide will be responsible for molecular screening and will bear all development costs during this process [3]. - Hanyu Pharmaceutical will pay up to 38 million yuan in milestone payments to Carbon Cloud Smart Peptide and will share revenue based on sales, with a maximum of 10% for North America and 3% for other global regions [3]. Group 2: Market Position and Product Development - Hanyu Pharmaceutical has established a strong position in the GLP-1 market, particularly with its experience in the development of liraglutide and other peptide products [4]. - The collaboration marks Hanyu Pharmaceutical's entry into the innovative research frontier of weight loss drugs, enhancing its global standing in the GLP-1 sector [4]. - The new drug is expected to show significant weight loss effects in preclinical studies, outperforming existing treatments like terzepatide in specific metrics [5][6].